Bausch + Lomb (NYSE:BLCO): Assessing Valuation After ASANA Lens Launch and Strong Clinical Updates

If you have been following Bausch + Lomb (NYSE:BLCO), the latest surge in its stock price may have grabbed your attention. After unveiling its new ASANA gas permeable lenses in the U.S., a portfolio geared toward patients with challenging vision needs, the company saw shares jump nearly 3%. This launch, backed by positive feedback on the product’s durability and versatility, seems to have landed well with investors who are watching for signs that Bausch + Lomb's innovation engine is gaining traction. The release coincides with upbeat results from clinical studies on other products, providing further fuel to market optimism about the company’s future.

Zooming out, Bausch + Lomb’s stock has had a mixed year. Despite the recent pop, the shares are still down about 2% over the past 12 months and roughly 16% for the year to date, pointing to lingering concerns. Yet, the strong 23% gain over the past 3 months signals that momentum is shifting. This may reflect renewed excitement around the company's pipeline and the possibility of a more supportive macro environment if borrowing costs ease. Adding to the narrative, recent product launches and published study results have started to reshape sentiment, signaling that Bausch + Lomb’s efforts to differentiate itself may be bearing fruit.

With the stock moving higher on fresh innovation, the real question is whether Bausch + Lomb is an undervalued growth story, or if the market is already pricing in its future gains.

Price-to-Sales of 1.1x: Is it justified?

According to widely accepted valuation metrics, Bausch + Lomb is currently trading at a price-to-sales (P/S) ratio of 1.1x. This figure suggests the stock is valued attractively relative to both industry peers and the broader sector.

The P/S ratio measures a company’s market capitalization against its annual revenue. This offers investors insight into how much they are paying for a dollar of revenue. For the medical equipment sector, this metric is particularly meaningful due to the growth focus and variable profitability among industry peers.

Bausch + Lomb’s relatively low multiple means the market may be underestimating its revenue-generating potential or overlooking improving fundamentals. Compared to industry averages, this could present a compelling entry point, especially for investors seeking value in the sector.

Result: Fair Value of $39.37 (UNDERVALUED)

See our latest analysis for Bausch + Lomb.

However, lingering losses and uncertain profit growth continue to pose risks that may temper optimism about Bausch + Lomb’s undervaluation story.

Find out about the key risks to this Bausch + Lomb narrative.

Another Perspective: Discounted Cash Flow

Looking at Bausch + Lomb through the lens of our DCF model offers a different perspective. This approach still suggests the shares are undervalued, but it relies on future cash flows and growth assumptions that can shift quickly. Could the reality for Bausch + Lomb end up differing from what both metrics suggest?

Look into how the SWS DCF model arrives at its fair value.

Stay updated when valuation signals shift by adding Bausch + Lomb to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

Build Your Own Bausch + Lomb Narrative

If you think this picture could look different, or want to bring your own analysis to the table, you can dig into the data and shape your own view in just a few minutes. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Bausch + Lomb.

Looking for More Smart Investment Angles?

Don’t limit your strategy to a single stock. Go further and uncover companies set to shape tomorrow’s markets using these curated ideas from the Simply Wall Street screener. If you act now, you could get ahead of the crowd and strengthen your portfolio with fresh opportunities.

• Unlock growth by starting with undervalued stocks based on cash flows to spot companies with strong cash flow that the market hasn’t caught onto yet.
• Target long-term financial security by checking out dividend stocks with yields > 3% for stocks paying out reliable yields above 3%.
• Join the forefront of medical innovation through healthcare AI stocks and see which firms are reshaping healthcare with artificial intelligence.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com